Skip to content

Research at St Andrews

Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!

Research output: Contribution to journalReview article


Leonard Amaral, Martin J. Boeree, Stephen H. Gillespie, Zarir F. Udwadia, Dick van Soolingen

School/Research organisations


Thioridazine (TDZ) has been shown to have in vitro activity against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis, to promote the killing of intracellular MDR and XDR strains and to cure the mouse of antibiotic-susceptible and -resistant pulmonary tuberculosis (TB) infections. Recently, TDZ was used to cure 10 of 12 XDR-TB patients in Buenos Aires, Argentina. At the time of writing, it is being used for the therapy of non-antibiotic-responsive terminal XDR-TB patients in Mumbai, India, on the basis of compassionate therapy and although it is too early to determine a cure, the patients have improved appetite, weight gain, are afebrile and free of night sweats, and their radiological picture shows great improvement. Because XDR-TB is essentially a terminal disease in many areas of the world and no new effective agents have yet to yield successful clinical trials, global clinical trials for the therapy of XDR-TB are urgently required. (C) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.



Original languageEnglish
Pages (from-to)524-526
Number of pages3
JournalInternational Journal of Antimicrobial Agents
Issue number6
Early online date25 Feb 2010
Publication statusPublished - Jun 2010

    Research areas

  • Pulmonary tuberculosis, Multidrug-resistant TB, Extensively drug-resistant TB, NEW-YORK-CITY, MYCOBACTERIUM-TUBERCULOSIS, EMERGENCE

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection

    Kloprogge, F., Hammond, R., Kipper, K., Gillespie, S. H. & Della Pasqua, O., 13 Sep 2019, In : Scientific Reports. 9, 8 p., 13228.

    Research output: Contribution to journalArticle

  2. A tuberculosis molecular bacterial load assay (TB-MBLA)

    Sabiiti, W., Mtafya, B. A., Alferes De Lima, D., Dombay, E., Baron, V. O., Azam, K., Orascova, K., Sloan, D. J. & Gillespie, S. H., 6 Sep 2019, (Accepted/In press) In : Journal of Visualized Experiments.

    Research output: Contribution to journalArticle

  3. Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

    Kloprogge, F., Hammond, R., Copas, A., Gillespie, S. H. & Della Pasqua, O., 25 Aug 2019, In : Journal of Antimicrobial Chemotherapy. Advance article, 7 p.

    Research output: Contribution to journalArticle

  4. Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

    Tweed, C. D., Crook, A. M., Dawson, R., Diacon, A. H., McHugh, T. D., Mendel, C. M., Meredith, S. K., Mohapi, L., Murphy, M. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M. & Gillespie, S. H., 14 Aug 2019, In : BMC Pulmonary Medicine. 19, 9 p., 152.

    Research output: Contribution to journalArticle

  5. Model-based relationship between the molecular bacterial load assay and time-to-positivity in liquid culture

    Svensson, R. J., Sabiiti, W., Kibiki, G. S., Ntinginya, N. E., Bhatt, N., Davies, G., Gillespie, S. H. & Simonsson, U. S. H., 29 Jul 2019, In : Antimicrobial Agents and Chemotherapy. Early

    Research output: Contribution to journalArticle

Related by journal

  1. Emergent and evolving antimicrobial resistance cassettes in community-associated fusidic acid and meticillin-resistant Staphylococcus aureus

    Ellington, M. J., Reuter, S., Harris, S. R., Holden, M. T. G., Cartwright, E. J., Greaves, D., Gerver, S. M., Hope, R., Brown, N. M., Török, M. E., Parkhill, J., Köser, C. U. & Peacock, S. J., May 2015, In : International Journal of Antimicrobial Agents. 45, 5, p. 477-484

    Research output: Contribution to journalArticle

  2. Antimicrobial treatment and clinical outcome for infections with carbapenem- and multiply-resistant Acinetobacter baumannii around London

    Livermore, D. M., Hill, R. L. R., Thomson, H., Charlett, A., Turton, J. F., Pike, R., Patel, B. C., Manuel, R., Gillespie, S., Balakrishnan, I., Barrett, S. P., Cumberland, N., Twagira, M. & C-MRAB Study Group, Jan 2010, In : International Journal of Antimicrobial Agents. 35, 1, p. 19-24 6 p.

    Research output: Contribution to journalArticle

ID: 9672334